Clinical Trial Update: A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Received BCG Immunisation 1 Month Previously [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety and immunogenicity of a recombinant MVA vaccine encoding antigen 85A (MVA-85A) delivered intradermally in healthy volunteers prev…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• MVA-85A vaccine (recombinant modified vaccinia Ankara expressing antigen 85A)

Snippet

Sponsor: University of Oxford | Conditions: Tuberculosis | Phase 1 | Status: COMPLETED